https://insights.citeline.com/hbw-insight/health/policy-and-regulation/regulation/blind-trust-in-artificial-intelligence-for-drug-production-misreads-us-fda-compliance-chart-IWOKTFXVLVGDBIPLBCDD55YQAM/2026-04-21T22:17:37.317Zalways0.5https://insights.citeline.com/resizer/ASbC_Gc2EBJ8ybIlvTktlBKZqHM=/cloudfront-us-east-1.images.arcpublishing.com/norstella/SV4SONXKGRAM5IHBCY4GA56MVM.jpghttps://insights.citeline.com/medtech-insight/business/r-and-d/clinical-trials/inbrain-concludes-enrollment-of-first-in-human-trial-using-graphene-neural-interface-QGHGV6BBSFFJZMUX7RHY3OLPAQ/2026-04-21T22:01:37.92Zalways0.5https://insights.citeline.com/resizer/AsWb1ecs2Uhx9WPk7gOGHPvXhdE=/cloudfront-us-east-1.images.arcpublishing.com/norstella/LGS34NCOYRGAFGAD5PZSLS4PAE.jpghttps://insights.citeline.com/medtech-insight/policy-and-regulation/eu/ai-medtech-regulation-in-limbo-after-eu-rules-simplification-XLJXY5H45ZHDTIGCDZBC4RRUAY/2026-04-21T21:49:09.202Zalways0.5https://insights.citeline.com/resizer/iklEGrqK4B3Mo1zvu3jcLRw1fSY=/cloudfront-us-east-1.images.arcpublishing.com/norstella/XIDGMQGNB5AXRJJR7HOAFKT4X4.jpghttps://insights.citeline.com/medtech-insight/policy-and-regulation/us-fda/with-commitment-letter-in-view-fda-takes-mdufa-vi-to-stakeholders-T3BZMIBXI5FWJBM6CDLYT6ETAE/2026-04-21T21:47:56.933Zalways0.5https://insights.citeline.com/resizer/lQqujKn-SwEvyUJefQNMgs0lE3Y=/cloudfront-us-east-1.images.arcpublishing.com/norstella/CRHDZQAXWFGBDDRF243XDSIADU.jpghttps://insights.citeline.com/pink-sheet/rare-diseases/rare-disease-advocates-question-added-value-of-fdas-plausible-mechanism-pathway-WBZ5QB2VVNDZDAXYP5NTADBK2Y/2026-04-21T21:27:24.667Zalways0.5https://insights.citeline.com/resizer/xOZ18pA5fU9fkSCxTQe2TiITS-k=/cloudfront-us-east-1.images.arcpublishing.com/norstella/GWT2HMV37RBEBL465J7E6EZX7U.jpghttps://insights.citeline.com/scrip/market-access/bayer-pledges-loyalty-to-europe-but-demands-more-support-PPRC2JGNQNAHPL6PHEUNUHUJLY/2026-04-21T21:13:51.224Zalways0.5https://insights.citeline.com/resizer/DL29Xt69f0t0NXp0uxX9euvoCiM=/cloudfront-us-east-1.images.arcpublishing.com/norstella/WFG62U77QFH2JLF2YCJULWIKMY.jpghttps://insights.citeline.com/scrip/market-intelligence/top-drugs/top-10-drugs-2025-keytruda-holds-the-crown-but-tirzepatide-is-coming-7S6K7VKWNZDSLO32N4S5H2YS6I/2026-04-21T21:11:47.93Zalways0.5https://insights.citeline.com/resizer/ZqSe1EHgULNReBfthy3bPTrtfN4=/cloudfront-us-east-1.images.arcpublishing.com/norstella/ZAEV7KXBXNLDBNFPVURBECKU54.jpghttps://insights.citeline.com/scrip/business/stock-watch/stock-watch-prospects-for-peace-help-jj-after-results-announcement-5FM574I6P5EIJC4UWE5LQS2ZVQ/2026-04-21T21:10:30.071Zalways0.5https://insights.citeline.com/resizer/C2OPQwdNNfpebAiYx0Hqthk9Vr8=/cloudfront-us-east-1.images.arcpublishing.com/norstella/OSNPEGFCONLXFMB22WMKNLI25M.jpghttps://insights.citeline.com/scrip/focus-on-asia/india/indias-trademark-regime-regulatory-gaps-patient-safety-risks-and-criminal-contempt-M2G2JP7O4VHFVGCK6V2433DNTM/2026-04-21T21:09:20.665Zalways0.5https://insights.citeline.com/resizer/AfOJFvOAjTnn7soGAUXV7hjdxIs=/cloudfront-us-east-1.images.arcpublishing.com/norstella/HSKRK2R5PJDQ7JT437JM5TMT5Y.jpghttps://insights.citeline.com/pink-sheet/market-access/government-payers/cms-prior-authorization-proposal-could-ease-processing-burden-costs-but-not-suppress-use-AZSYVJ6WSZFS7M7FVKAGIABORE/2026-04-21T21:08:25.955Zalways0.5https://insights.citeline.com/resizer/XGbue-wRutMvtZtxIosRixKYc90=/cloudfront-us-east-1.images.arcpublishing.com/norstella/3DOVFRKCPVD3NODRXD2HMZGVRE.jpghttps://insights.citeline.com/scrip/r-and-d/clinical-trials/astrazenecas-ultomiris-hits-interim-phase-iii-endpoint-in-igan-eyes-accelerated-filings-PYPAM2WS35BTHKUAMCTFJCBPXA/2026-04-21T21:08:19.738Zalways0.5https://insights.citeline.com/resizer/urNxbUON-FM9U5VdvnyjqDIgKTE=/cloudfront-us-east-1.images.arcpublishing.com/norstella/FE4NUFO54FIUVLFJS4XJMUKO5U.jpghttps://insights.citeline.com/scrip/r-and-d/clinical-trials/merck-and-eisais-keytrudalenvimawelireg-trial-in-kidney-cancer-fails-4Y4GLHJNSNEKJEEHU4DP3SKAWI/2026-04-21T21:03:17.229Zalways0.5https://insights.citeline.com/resizer/WxX9Xf9eEgIB2Bb9MbdNKmAlvpk=/cloudfront-us-east-1.images.arcpublishing.com/norstella/UP76E7SA6BEEZI57KMIZNYSS5E.jpghttps://insights.citeline.com/scrip/therapeutic-category/cardiovascular/bioage-outlines-clinical-expansion-plans-for-bge-102-G3EBRD5MCRC35FFYPRDOAQNEHQ/2026-04-21T21:01:58.586Zalways0.5https://insights.citeline.com/resizer/aukOI4oyRF0xvM8c7mtbbwU9fYQ=/cloudfront-us-east-1.images.arcpublishing.com/norstella/U5JLXIX3IVG2JPOO4JKXGYRNHY.jpghttps://insights.citeline.com/scrip/therapeutic-category/neurological/xenons-azetukalner-confirms-phase-iii-efficacy-signal-sets-up-mid-year-nda-filing-LMWTN7E62FHT5KXGGZIVSX4FYU/2026-04-21T18:07:42.691Zalways0.5https://insights.citeline.com/resizer/af0zdvtskKKUyn44sRQ8QYe-jDo=/cloudfront-us-east-1.images.arcpublishing.com/norstella/TICVZAZYEFDGDBVBMFG6TH3LTY.jpghttps://insights.citeline.com/medtech-insight/device-area/respiratory/storm-pe-90-day-data-cavt-patients-walk-111-meters-further-than-anticoagulation-alone-J3OB7QIPZZDKPBUK66IXVYLPPI/2026-04-21T17:56:39.934Zalways0.5https://insights.citeline.com/resizer/ueD2FozaaYgOMVGv_NYvZnTVjEw=/cloudfront-us-east-1.images.arcpublishing.com/norstella/ASJJNLULWZEPJGXBIUUJF4NVPE.jpghttps://insights.citeline.com/medtech-insight/digital-technologies/ai/study-reveals-how-people-talk-to-ai-about-health-PVC22MWSBRA2HHRTKFT3YNXLV4/2026-04-21T16:20:43.407Zalways0.5https://insights.citeline.com/resizer/vUX4tRTgGIpknPswpalhSlHGduw=/cloudfront-us-east-1.images.arcpublishing.com/norstella/RBWKR7FA4NNDZECY3ZV2BIY5Y4.pnghttps://insights.citeline.com/scrip/business/supply-chain/prolonged-us-blockade-of-iran-ports-risks-drug-shortages-wider-supply-chain-woes-SEMZ4LNEPVA63KV7XAUFT6VCJY/2026-04-21T16:09:02.386Zalways0.5https://insights.citeline.com/resizer/_ynXHk6n6kXasqPeYEY4TEGwTDQ=/cloudfront-us-east-1.images.arcpublishing.com/norstella/6B2NLA3LNBDAPKLB4OGCGYCEJI.jpghttps://insights.citeline.com/pink-sheet/product-reviews/eu-chmp/ema-decision-time-for-novartis-intrathecal-sma-gene-therapy-five-others-KLNUMWSBQBD3LPQWCQ5RIRJX24/2026-04-21T15:27:14.256Zalways0.5https://insights.citeline.com/resizer/DCCHegvvMjDr3GxiNkzWUOxz2bg=/cloudfront-us-east-1.images.arcpublishing.com/norstella/ZCCEAJHICZLQTAQVOBEYDVNVAU.jpghttps://insights.citeline.com/hbw-insight/beauty/policy-and-regulation/qa-with-dsm-firmenich-on-parsol-shields-expected-impact-on-us-market-WVMHFVXYWFB6ZHCLZFNHBMFDLY/2026-04-21T15:24:46.91Zalways0.5https://insights.citeline.com/resizer/9F7bGyotii8oszC2af9N_JmWsQE=/cloudfront-us-east-1.images.arcpublishing.com/norstella/NTL5IBEOTJHSFI4B25I6BCS7QY.jpghttps://insights.citeline.com/pink-sheet/product-reviews/eu-chmp/vijoice-back-on-the-table-as-novartis-set-to-discuss-new-alpelisib-filing-with-ema-2V5GN3YBKFCA3AN4IFH7U5NQ2Y/2026-04-21T15:21:41.765Zalways0.5https://insights.citeline.com/resizer/lmhgvCrIiKC31_bbUxcypkLbp6w=/cloudfront-us-east-1.images.arcpublishing.com/norstella/7OHFKL5XAJFEZKBIPTYMW6M2BQ.jpghttps://insights.citeline.com/pink-sheet/pathways-and-standards/review-pathways/us-fda-looks-beyond-monoclonal-antibodies-to-encourage-animal-testing-alternatives-B4IC4F2BOFAJXME33BKWL4FQEA/2026-04-21T14:01:59.051Zalways0.5https://insights.citeline.com/resizer/XjEK8yy69rYtmYy1v22n4bKexI4=/cloudfront-us-east-1.images.arcpublishing.com/norstella/B4SYG2UZARFO5A6Q52RJRIOOP4.jpghttps://insights.citeline.com/medtech-insight/market-access/medical-device-repair-controversy-back-in-play-OBTXKQL4GBBA5I5S2SLXQ6GJXA/2026-04-21T13:22:31.159Zalways0.5https://insights.citeline.com/resizer/MdOAjj8-7V_0SiXq8lVzjkgypUk=/cloudfront-us-east-1.images.arcpublishing.com/norstella/XPB6SZZNEVEP3DFRIU7IYAVPKQ.jpghttps://insights.citeline.com/pink-sheet/pathways-and-standards/psychedelic-access-could-extend-beyond-us-right-to-try-pathway-OCTXM6CHXRDJHGXY5JWX2H2RFI/2026-04-21T13:18:17.941Zalways0.5https://insights.citeline.com/resizer/F9syaFE5XJ2yVHxaAboW99x584I=/cloudfront-us-east-1.images.arcpublishing.com/norstella/55WMB65YKZBU3PJ4FAOUTY2B7I.jpghttps://insights.citeline.com/scrip/r-and-d/clinical-trials/nektar-charts-rezpegs-late-stage-development-in-alopecia-areata-on-long-term-phase-ii-data-GQIQFRRLZJAC7AAWKLZHQZWXHM/2026-04-21T12:22:39.305Zalways0.5https://insights.citeline.com/resizer/qFo5YipBBhtWZ6WfSpgAaXvM5rQ=/cloudfront-us-east-1.images.arcpublishing.com/norstella/UFADG24SWZGV5KEC7BXCPK5E7Q.jpghttps://insights.citeline.com/generics-bulletin/products/biosimilars/canadas-jamp-deepens-immunology-biosimilars-push-IGV5F65LZVDDBJH5HIVO32O55M/2026-04-21T10:33:44.395Zalways0.5https://insights.citeline.com/resizer/LOdkXkqf7mHopO2jaZxu0brHQH4=/cloudfront-us-east-1.images.arcpublishing.com/norstella/WEWTQVUH6FJTJIKO3XTCK4U7QU.jpghttps://insights.citeline.com/pink-sheet/regional-comparisons/indias-trademark-regime-regulatory-blind-spot-patient-safety-and-case-laws-to-heed-K3VYMWZACVCWTJHYRLKWKEWUME/2026-04-21T09:23:39.297Zalways0.5https://insights.citeline.com/resizer/AfOJFvOAjTnn7soGAUXV7hjdxIs=/cloudfront-us-east-1.images.arcpublishing.com/norstella/HSKRK2R5PJDQ7JT437JM5TMT5Y.jpghttps://insights.citeline.com/scrip/r-and-d/clinical-trials/argenx-shows-deepening-responses-for-vyvgart-across-the-mg-spectrum-U2YW3PVX5VDCPDOBJADCXFNJQU/2026-04-21T09:20:37.282Zalways0.5https://insights.citeline.com/resizer/KvRg6gnTWwzAfj98RD3nT3qh6cg=/cloudfront-us-east-1.images.arcpublishing.com/norstella/YBIZ7GCCY5OQHA4VFEZ3DRL22M.jpghttps://insights.citeline.com/pink-sheet/pathways-and-standards/review-pathways/us-fda-wants-feedback-on-cnpvs-start-by-releasing-the-reviews-GI3E266LSRD27OANOL4N4UYGO4/2026-04-21T09:11:50.806Zalways0.5https://insights.citeline.com/resizer/StcnuYuvxQHqWo5UXbCJ2CdnDQw=/cloudfront-us-east-1.images.arcpublishing.com/norstella/U53ZN3FPKZETTDYDOAHFYID4WI.jpghttps://insights.citeline.com/pink-sheet/pathways-and-standards/trump-executive-order-supercharges-psychedelic-sector-with-psilocybin-at-head-of-the-line-OW4ILCQ4IVGUFEG5GHGSYG3QBQ/2026-04-21T09:11:10.288Zalways0.5https://insights.citeline.com/resizer/lk4j7Aa-NrNqq2BbK3mMv78-j-Q=/cloudfront-us-east-1.images.arcpublishing.com/norstella/WP4MJ5JYJNCIXA26M7W2TQDFBA.jpghttps://insights.citeline.com/pink-sheet/product-reviews/eu-chmp/new-eu-filings-TB5JGPOFXRCRNFSTQDMLU6ODZA/2026-04-21T07:40:01.365Zalways0.5https://insights.citeline.com/resizer/qr4HqLM3X7pfzfb_UShZ54G3B6w=/cloudfront-us-east-1.images.arcpublishing.com/norstella/R2VDCMSQWVJTVG72SZJTX6TEA4.jpghttps://insights.citeline.com/pink-sheet/legislation/eu-pharma-legislation-reform/eu-pharma-reform-supply-obligations-burdensome-for-smes-warns-eucope-HFOHHJJ6ARDXPHAJOZE3YQ5QC4/2026-04-21T07:38:53.929Zalways0.5https://insights.citeline.com/resizer/MAJL4d1J7TWLMi0a-3XPMEVUAOE=/cloudfront-us-east-1.images.arcpublishing.com/norstella/TMVVSSRQKVBIFI5DA22G7C3XN4.jpghttps://insights.citeline.com/medtech-insight/business/deals/medtronic-adds-ffrangio-to-cardiovascular-arsenal-in-585m-cathworks-acquisition-N2A4FYQHJJH4HBTSS3NNE6BECA/2026-04-21T07:11:39.985Zalways0.5https://insights.citeline.com/resizer/DIOHbWe8RnL3Vr72C4ftQoHxEPE=/cloudfront-us-east-1.images.arcpublishing.com/norstella/KXV77PQ6LNAB5C3NI55FN75ZGA.jpghttps://insights.citeline.com/scrip/r-and-d/clinical-trials/aacr-hansohs-adc-impresses-in-io-combo-for-2l-nsclc-UCFI2OOJDJCNTDYVAHQXYEO75Q/2026-04-21T06:50:08.438Zalways0.5https://insights.citeline.com/resizer/YkUOAK2ypJx9ipWjF9LVQ_TA6uw=/cloudfront-us-east-1.images.arcpublishing.com/norstella/FS3KLGR2BRFX3GZCMRGF6GUJMU.jpghttps://insights.citeline.com/in-vivo/business-strategy/ai/graph-intelligence-in-clinical-trials-explainability-will-make-or-break-it-J2FLTGQW2BB4LBOIJBPGIJKXPI/2026-04-21T06:20:43.919Zalways0.5https://insights.citeline.com/resizer/YALpNO5TGrPdqjmEmeSZZ5mrULQ=/cloudfront-us-east-1.images.arcpublishing.com/norstella/Y35GYE2KQBHBFEOJ6H6MY7TPU4.jpghttps://insights.citeline.com/scrip/leadership/interviews/alphamabs-bispecific-phase-iii-win-in-breast-cancer-lays-runway-for-take-off-W62ZI5XSDVCOFKM5EC22EKFUHQ/2026-04-21T04:29:12.905Zalways0.5https://insights.citeline.com/resizer/QByWLYYFLGqGlKoxCfQhv78uD0k=/cloudfront-us-east-1.images.arcpublishing.com/norstella/N7TOWQXANFKJXIT5B3BTKRDHBM.jpghttps://insights.citeline.com/scrip/r-and-d/clinical-trials/could-pd-l1vegf-agents-face-off-first-in-china-phase-iii-trials-2G3GAKRRENGN3FTPN5NH4YAMAY/2026-04-21T04:23:04.91Zalways0.5https://insights.citeline.com/resizer/FHMEcHzrKs-PboNzp5wfJvugXHc=/cloudfront-us-east-1.images.arcpublishing.com/norstella/YN4EUIC3CBG3JAEOJQMMTN7CW4.jpghttps://insights.citeline.com/hbw-insight/health/policy-and-regulation/regulation/acnus-simultaneous-otcrx-access-requirement-criticized-by-chpa-phrma-supported-by-aam-PRB4K47BTZBYDNOYKHM5RBWTHQ/2026-04-21T02:55:26.801Zalways0.5https://insights.citeline.com/resizer/vrton4FnP3NC--4C-YibKjyOT6s=/cloudfront-us-east-1.images.arcpublishing.com/norstella/MJ25OLM2WRBM5H3ZGO4533NS2Y.jpghttps://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-KROBJCLAKVFBLCZ7BGBGCE3VDQ/2026-04-21T01:45:00.088Zalways0.5https://insights.citeline.com/resizer/yYwvRVmhblLIMA0HOvUK6LfqRwQ=/cloudfront-us-east-1.images.arcpublishing.com/norstella/G7XLNG5DWRIZTCTW357HEKFDOE.jpghttps://insights.citeline.com/companies/shanghai-stexo-biotechnology-co-ltd/2026-04-21T00:08:36.951Zalways0.5https://insights.citeline.com/companies/quantori/2026-04-21T00:08:28.737Zalways0.5https://insights.citeline.com/companies/jilin-lihua-pharmaceutical-factory-co-ltd/2026-04-21T00:08:20.604Zalways0.5https://insights.citeline.com/companies/shanghai-epiprobe-biotechnology-co-ltd/2026-04-21T00:08:16.542Zalways0.5https://insights.citeline.com/companies/biometas-group/2026-04-21T00:08:12.563Zalways0.5https://insights.citeline.com/companies/zshk-laboratories-limited/2026-04-21T00:08:08.585Zalways0.5https://insights.citeline.com/companies/vanarix/2026-04-21T00:08:04.619Zalways0.5https://insights.citeline.com/companies/beeline-medicines/2026-04-21T00:08:00.358Zalways0.5https://insights.citeline.com/companies/xennials-therapeutics-inc/2026-04-21T00:07:56.4Zalways0.5https://insights.citeline.com/companies/tonrol-bio-pharmaceutical/2026-04-21T00:07:52.234Zalways0.5https://insights.citeline.com/companies/deproco-inc/2026-04-21T00:07:48.132Zalways0.5https://insights.citeline.com/companies/innoup-farma-sl/2026-04-21T00:07:44.287Zalways0.5https://insights.citeline.com/companies/xinjiang-bai-hua-cun-pharma-tech-coltd/2026-04-21T00:07:40.261Zalways0.5https://insights.citeline.com/companies/newbio-therapeutics/2026-04-21T00:07:36.229Zalways0.5https://insights.citeline.com/companies/shengyuan-zetong-shanghai-pharmaceutical-co-ltd/2026-04-21T00:07:32.126Zalways0.5https://insights.citeline.com/companies/reyoung-pharmaceutical-co-ltd/2026-04-21T00:07:28.006Zalways0.5https://insights.citeline.com/companies/simcere-zaiming/2026-04-21T00:07:24.055Zalways0.5https://insights.citeline.com/companies/albega-medical-gmbh/2026-04-21T00:07:20.314Zalways0.5https://insights.citeline.com/companies/scribe-biosciences/2026-04-21T00:07:16.325Zalways0.5https://insights.citeline.com/companies/mynvax/2026-04-21T00:07:12.104Zalways0.5https://insights.citeline.com/companies/zhejiang-tianyuan-bio-pharmaceutical/2026-04-21T00:07:07.986Zalways0.5https://insights.citeline.com/companies/adbiotech-co-ltd/2026-04-21T00:07:03.973Zalways0.5https://insights.citeline.com/companies/biochemie-gmbh/2026-04-21T00:06:59.773Zalways0.5https://insights.citeline.com/companies/jiangxi-yuanchao-medical-technology-co-ltd/2026-04-21T00:06:55.701Zalways0.5https://insights.citeline.com/companies/jinling-pharmaceutical-co-ltd/2026-04-21T00:06:51.767Zalways0.5https://insights.citeline.com/companies/clee-medical-sa2026-04-21T00:06:43.77Zalways0.5https://insights.citeline.com/companies/damora-therapeutics-inc2026-04-21T00:06:39.71Zalways0.5https://insights.citeline.com/companies/glycanostics/2026-04-21T00:06:35.722Zalways0.5https://insights.citeline.com/companies/hoola-therapeutics-inc2026-04-21T00:06:31.77Zalways0.5https://insights.citeline.com/companies/paras-biopharmaceuticals-finland-oy2026-04-21T00:06:27.689Zalways0.5https://insights.citeline.com/companies/quipt-home-medical2026-04-21T00:06:23.824Zalways0.5https://insights.citeline.com/companies/huapu-shijiazhuang-pharmaceutical2026-04-21T00:06:19.581Zalways0.5https://insights.citeline.com/companies/crossbridge-bio-inc2026-04-21T00:06:11.537Zalways0.5https://insights.citeline.com/companies/neurometrix2026-04-21T00:06:07.603Zalways0.5https://insights.citeline.com/companies/cdt-equity-inc2026-04-21T00:06:03.455Zalways0.5https://insights.citeline.com/companies/correctsequence-therapeutics-co-ltd2026-04-21T00:05:58.513Zalways0.5https://insights.citeline.com/companies/octane-medical-group2026-04-21T00:05:52.528Zalways0.5https://insights.citeline.com/companies/mercury-bio2026-04-21T00:05:46.458Zalways0.5https://insights.citeline.com/companies/hexaell-biotech-co-ltd2026-04-21T00:05:40.689Zalways0.5https://insights.citeline.com/companies/karuna-therapeutics-inc2026-04-21T00:05:34.601Zalways0.5https://insights.citeline.com/companies/vdyne-inc2026-04-21T00:05:29.733Zalways0.5https://insights.citeline.com/companies/third-harmonic-bio-inc2026-04-21T00:05:22.279Zalways0.5https://insights.citeline.com/companies/swiss-rockets-ag2026-04-21T00:05:16.545Zalways0.5https://insights.citeline.com/companies/biolamina-ab2026-04-21T00:05:10.283Zalways0.5https://insights.citeline.com/companies/venus-concept-inc2026-04-21T00:05:04.632Zalways0.5https://insights.citeline.com/companies/clinica-universidad-de-navarra2026-04-21T00:04:52.164Zalways0.5https://insights.citeline.com/companies/dermtech-inc2026-04-21T00:04:46.225Zalways0.5https://insights.citeline.com/companies/inhibrx-inc2026-04-21T00:04:39.946Zalways0.5https://insights.citeline.com/companies/inion-oy2026-04-21T00:04:34.086Zalways0.5https://insights.citeline.com/companies/nova-biomedical-corp2026-04-21T00:04:28.177Zalways0.5https://insights.citeline.com/companies/rush-university-medical-center2026-04-21T00:04:22.007Zalways0.5https://insights.citeline.com/companies/chronogen-inc2026-04-21T00:04:15.977Zalways0.5https://insights.citeline.com/companies/generation-bio-co2026-04-21T00:04:10.165Zalways0.5https://insights.citeline.com/companies/igm-biosciences-inc2026-04-21T00:04:04.013Zalways0.5https://insights.citeline.com/companies/cns-pharmaceuticals-inc2026-04-21T00:03:58.118Zalways0.5https://insights.citeline.com/companies/obsidian-therapeutics-inc2026-04-21T00:03:51.71Zalways0.5https://insights.citeline.com/companies/atreca-inc2026-04-21T00:03:45.718Zalways0.5https://insights.citeline.com/companies/applied-therapeutics-inc2026-04-21T00:03:33.793Zalways0.5https://insights.citeline.com/companies/sqz-biotechnologies-company2026-04-21T00:03:27.599Zalways0.5https://insights.citeline.com/companies/bioxcel-therapeutics-inc2026-04-21T00:03:21.636Zalways0.5https://insights.citeline.com/companies/evelo-biosciences-inc2026-04-21T00:03:15.524Zalways0.5https://insights.citeline.com/companies/antibe-therapeutics-inc2026-04-21T00:03:03.459Zalways0.5https://insights.citeline.com/companies/ht-presspart2026-04-21T00:02:57.503Zalways0.5https://insights.citeline.com/companies/inari-medical-inc2026-04-21T00:02:51.414Zalways0.5https://insights.citeline.com/companies/sutro-biopharma-inc2026-04-21T00:02:39.466Zalways0.5https://insights.citeline.com/companies/eiger-biopharmaceuticals-inc2026-04-21T00:02:33.479Zalways0.5https://insights.citeline.com/companies/avillion-llp2026-04-21T00:02:27.743Zalways0.5https://insights.citeline.com/companies/dmk-pharmaceuticals-corp2026-04-21T00:02:21.332Zalways0.5https://insights.citeline.com/companies/seres-therapeutics-inc2026-04-21T00:02:15.35Zalways0.5https://insights.citeline.com/companies/hologic-inc2026-04-21T00:02:09.251Zalways0.5https://insights.citeline.com/companies/curevac-nv2026-04-21T00:02:03.475Zalways0.5https://insights.citeline.com/companies/bioasis-technologies-inc2026-04-21T00:01:57.188Zalways0.5https://insights.citeline.com/companies/nanostring-technologies-inc2026-04-21T00:01:51.528Zalways0.5https://insights.citeline.com/companies/calliditas-therapeutics-ab2026-04-21T00:01:45.206Zalways0.5https://insights.citeline.com/companies/scorpius-holdings-inc2026-04-21T00:01:39.332Zalways0.5https://insights.citeline.com/companies/sunshine-biopharma-inc2026-04-21T00:01:33.183Zalways0.5https://insights.citeline.com/companies/gyre-therapeutics-inc2026-04-21T00:01:27.499Zalways0.5https://insights.citeline.com/companies/bionomics-limited2026-04-21T00:01:21.354Zalways0.5https://insights.citeline.com/companies/eli-lilly-and-company2026-04-21T00:01:14.992Zalways0.5https://insights.citeline.com/companies/servier/2026-04-21T00:01:09.15Zalways0.5